More Articles

EBE reveals Europe’s biosimilar pricing and reimbursement policies landscape Biosimilars/Research | Posted 15/02/2018

The first biosimilar was approved in the European Union (EU) in 2006. Since then, biosimilar policies have been developed with a focus on increasing biosimilar uptake. However, the extent to which...

EMA approval for biosimilar insulin glargine Semglee Biosimilars/News | Posted 15/02/2018

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 25 January 2018 that it had recommended granting marketing authorization for the insulin gla...

Quality and clinical performance of biopharmaceuticals Biosimilars/Research | Posted 15/02/2018

A review carried out by researchers from Sandoz describes the inherent nature of biopharmaceutical heterogeneity and discusses modern quality systems and regulatory frameworks used to maintain biop...

Building confidence in biosimilars Reports | Posted 15/02/2018

The third Multi-stakeholder Workshop on Biosimilar Medicinal Products included a session on ‘Building Stakeholder Confidence in Biosimilar Medicines through Evidence-Based Information Sharing’ [1]....

Europe calls for more drugs repurposing Generics/General | Posted 15/02/2018

The European Commission (EC) published a paper for the 8th Meeting of the STAMP Expert Group on 8 December 2017 regarding case studies on repurpose medicines which outlined some of the issues that...

Biocon and Sandoz join forces for global next-generation biosimilars Pharma News | Posted 15/02/2018

On 18 January 2018, Biocon and Sandoz announced a global partnership to develop, manufacture and commercialize new next-generation biosimilars that will be available worldwide. This collaboration a...

Efficacy and safety of generic imatinib after switching Generics/Research | Posted 15/02/2018

A study carried out by researchers from the US investigated switching from originator to generic imatinib in patients treated for chronic myeloid leukaemia [1].

Zarxio reveals all: the US biosimilars market Biosimilars/Research | Posted 09/02/2018

Launched in 2015, Zarxio (filgrastim-sndz) was the first biosimilar to gain US Food and Drug Administration (FDA) approval [1]. It competes with Neupogen (its reference product), Granix and Neulast...